{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:26:00Z","timestamp":1789979160015,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2010 national Programme Hospitalier de Recherche Clinique programme"},{"name":"Amgen, Fresenius Medical Care and GlaxoSmithKline"},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lilly France"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme-Chibret"},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Genzyme"},{"name":"Vifor Fresenius"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Elderly patients with chronic kidney disease (CKD) are often excluded from clinical trials; this may affect their use of essential drugs for cardiovascular complications. We sought to assess the impact of age on cardiovascular drug use in elderly patients with CKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used baseline data from the Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort including 3033 adult patients with CKD Stages 3 and 4. We studied the use of recommended drugs for coronary artery disease (CAD), stroke and atrial fibrillation by age, after adjusting for socio-demographic and clinical conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patients\u2019 mean age was 66.8\u2009years (mean estimated glomerular filtration rate 32.9\u2009mL\/min\/1.73\u2009m2). The prevalence of CAD was 24.5% [81.3% receiving antiplatelet agents, 75.6% renin\u2013angiotensin system (RAS) blockers, 65.4% \u03b2-blockers and 81.3% lipid-lowering therapy], that of stroke 10.0% (88.8% receiving antithrombotic drugs) and that of atrial fibrillation 11.1% (69.5% receiving oral anticoagulants). Compared with patients aged &amp;lt;65 years, older age (\u226565\u2009years) was associated with greater use of antithrombotic drugs in stroke [adjusted odds ratio (aOR) (95% confidence interval)\u2009=\u20092.83 (1.04\u20137.73) for patients aged (75\u201384 years)] and less use of RAS blockers [aOR\u2009=\u20090.39 (0.16\u20130.89) for patients aged \u226585 years], \u03b2-blockers [aOR\u2009=\u20090.31 (0.19\u20130.53) for patients aged 75\u201384 years] and lipid-lowering therapy [aOR\u2009=\u20090.39 (0.15\u20131.02) for patients aged \u226585 years, P for trend\u2009=\u20090.01] in CAD. Older age was not associated with less use of antiplatelet agents in CAD or oral anticoagulants in atrial fibrillation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with CKD, older age per se was not associated with the underuse of antithrombotic drugs but was for other major drugs, with a potential impact on cardiovascular outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfz063","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T03:05:10Z","timestamp":1556334310000},"page":"199-207","source":"Crossref","is-referenced-by-count":12,"title":["Impact of age on cardiovascular drug use in patients with chronic kidney disease"],"prefix":"10.1093","volume":"13","author":[{"given":"C\u00e9dric","family":"Villain","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie-Dialyse, CHU Ambroise Par\u00e9, APHP, Boulogne-Billancourt, France"},{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"first","affiliation":[{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Service de Pharmacologie Clinique, D\u00e9partement de Recherche Clinique, CHU d\u2019Amiens, Universit\u00e9 de Picardie Jules Verne, INSERM U-1088, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Metzger","sequence":"first","affiliation":[{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Combe","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie Transplantation Dialyse Aph\u00e9r\u00e8ses, CHU de Bordeaux, Bordeaux, France"},{"name":"INSERM Unit\u00e9 1026, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fouque","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lyon, Service de N\u00e9phrologie, CarMeN INSERM 1060, Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Frimat","sequence":"first","affiliation":[{"name":"CHRU Nancy-Brabois, Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"INSERM CIC-EC CIE6 - EA 4360 Apemac, Nancy Universit\u00e9, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacquelinet","sequence":"first","affiliation":[{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Agence de Biom\u00e9decine, La Plaine Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Laville","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lyon, Service de N\u00e9phrologie, CarMeN INSERM 1060, Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Brian\u00e7on","sequence":"first","affiliation":[{"name":"INSERM CIC-EC CIE6 - EA 4360 Apemac, Nancy Universit\u00e9, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Pisoni","sequence":"first","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mansencal","sequence":"first","affiliation":[{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Service de Cardiologie, CHU Ambroise Par\u00e9, APHP, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Stengel","sequence":"first","affiliation":[{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A","family":"Massy","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie-Dialyse, CHU Ambroise Par\u00e9, APHP, Boulogne-Billancourt, France"},{"name":"CESP, INSERM Unit\u00e9 1018, Equipe 5 EpRec, Universit\u00e9 Paris-Sud, UVSQ, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"2020041009152801900_sfz063-B1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jama.2013.252441","article-title":"Change in prevalence of reduced estimated glomerular filtration rate among the oldest-old US adults from 1988\u20131994 through 2005\u20132010","volume":"310","author":"Bowling","year":"2013","journal-title":"JAMA"},{"key":"2020041009152801900_sfz063-B2","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"key":"2020041009152801900_sfz063-B3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2020041009152801900_sfz063-B4","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy277","article-title":". Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease","author":"Villain","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2020041009152801900_sfz063-B5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2020041009152801900_sfz063-B6","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2020041009152801900_sfz063-B7","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"2020041009152801900_sfz063-B8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","article-title":"Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"2020041009152801900_sfz063-B9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.atherosclerosis.2014.10.108","article-title":"Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients \u2265 80 years of age: observations from the CREDO-Kyoto Registry Cohort-2","volume":"237","author":"Natsuaki","year":"2014","journal-title":"Atherosclerosis"},{"key":"2020041009152801900_sfz063-B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2020041009152801900_sfz063-B11","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1532-5415.2009.02483.x","article-title":"Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time","volume":"57","author":"Ali","year":"2009","journal-title":"J Am Geriat Soc"},{"key":"2020041009152801900_sfz063-B12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/STROKEAHA.110.580209","article-title":"Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register","volume":"41","author":"Asberg","year":"2010","journal-title":"Stroke"},{"key":"2020041009152801900_sfz063-B13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jgs.14855","article-title":"Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation: results from the ReAl-life Multicenter Survey Evaluating Stroke Study","volume":"65","author":"Biteker","year":"2017","journal-title":"J Am Geriat Soc"},{"key":"2020041009152801900_sfz063-B14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.archger.2016.04.008","article-title":"The role of comprehensive geriatric assessment and functional status in evaluating the patterns of antithrombotic use among older people with atrial fibrillation","volume":"65","author":"Mazzone","year":"2016","journal-title":"Arch Gerontol Geriat"},{"key":"2020041009152801900_sfz063-B15","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/ndt\/gft388","article-title":"The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study","volume":"29","author":"Stengel","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020041009152801900_sfz063-B16","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2020041009152801900_sfz063-B17","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"2020041009152801900_sfz063-B18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jacc.2013.12.042","article-title":"Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS Study (REasons for Geographic And Racial Differences in Stroke)","volume":"63","author":"Brown","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2020041009152801900_sfz063-B19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2215\/CJN.07290810","article-title":"Kidney function and long-term medication adherence after myocardial infarction in the elderly","volume":"6","author":"Chang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020041009152801900_sfz063-B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cjca.2013.07.680","article-title":"Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry","volume":"30","author":"Gandhi","year":"2014","journal-title":"Can J Cardiol"},{"key":"2020041009152801900_sfz063-B21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.amjcard.2016.08.042","article-title":"Relation of statin use and mortality in community-dwelling frail older patients with coronary artery disease","volume":"118","author":"Pilotto","year":"2016","journal-title":"Am J Cardiol"},{"key":"2020041009152801900_sfz063-B22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.04.006","article-title":"Frequency of use of statins and aspirin in patients with previous coronary artery bypass grafting","volume":"118","author":"Curl","year":"2016","journal-title":"Am J Cardiol"},{"key":"2020041009152801900_sfz063-B23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp-2012-303267","article-title":"Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications","volume":"84","author":"B\u00e9jot","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020041009152801900_sfz063-B24","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1161\/STROKEAHA.109.558759","article-title":"Age disparities in stroke quality of care and delivery of health services","volume":"40","author":"Saposnik","year":"2009","journal-title":"Stroke"},{"key":"2020041009152801900_sfz063-B25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1573403X1103150514155757","article-title":"Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease","volume":"11","author":"Agrawal","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"2020041009152801900_sfz063-B26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","article-title":"Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis","volume":"51","author":"Afilalo","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020041009152801900_sfz063-B27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2020041009152801900_sfz063-B28","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":". J Am Coll Cardiol"},{"key":"2020041009152801900_sfz063-B29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2016.10.017","article-title":"The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation","volume":"91","author":"Keskar","year":"2017","journal-title":"Kidney Int"},{"key":"2020041009152801900_sfz063-B30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jgs.14483","article-title":"Management of atrial fibrillation in elderly adults","volume":"65","author":"Desai","year":"2017","journal-title":"J Am Geriat Soc"},{"key":"2020041009152801900_sfz063-B31","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1212\/WNL.0b013e31822f0423","article-title":"Secondary preventive medication persistence and adherence 1 year after stroke","volume":"77","author":"Bushnell","year":"2011","journal-title":"Neurology"},{"key":"2020041009152801900_sfz063-B32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/STROKEAHA.109.566950","article-title":"Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke","volume":"41","author":"Glader","year":"2010","journal-title":"Stroke"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/2\/199\/33028149\/sfz063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/2\/199\/33028149\/sfz063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:15:52Z","timestamp":1586524552000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/2\/199\/5513295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6,10]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz063","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,6,10]]}}}